ClinicalTrials.gg
CompletedNCT02998840Updated Sep 15, 2022Results posted

A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure

A Phase 2 interventional study of B244 and Vehicle in Prehypertension and Hypertension, Stage I, sponsored by AOBiome LLC. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-15.

Sponsored by AOBiome LLC · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Prehypertension with a site in United States — 6 open to participants now, 7 under way, 1 of them phase 3. Prehypertension · United States.

Enrollment
13th of 76
132 · median 60
Started
2016
with 6 others
Phase 2
7 of 82
none open now
Registered
48th of 82
by date

Among the 82 studies in Prehypertension with a site in United States, this one is the 13th largest by enrollment of the 76 interventional ones that give a count, is one of 7 that started in 2016, is one of 7 in phase 2, and was the 48th registered.

Prehypertension

158 studies on the registry are indexed under Prehypertension; 21 are open to participants now.

Browse Prehypertension studies →

Open to participants now

6 of the 82 studies in Prehypertension with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Prehypertension studies recruiting now, 3 (27%) set no upper age limit and 7 (64%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Prehypertension with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate and compare the efficacy of B244 in treating patients with hypertension.

Read the detailed description

This is a Prospective, Vehicle Controlled, Double Blinded, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 4 weeks vs vehicle application on BP and inflammatory biomarkers.

03

Conditions studied

  • Prehypertension
  • Hypertension, Stage I

Keywords

  • elevated blood pressure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects ≥18 years of age
  • In good general health as determined by a thorough medical history and physical examination, and vital signs
  • Clinical diagnosis of elevated Blood Pressure defined as:

    • Having systolic prehypertension measurements having systolic BP (mmHg) of 120-139 and Diastolic BP (mmHg) of 90
    • OR
    • Having systolic Stage 1 hypertension measurements having systolic BP (mmHg) of 140-159 and Diastolic BP (mmHg) of 100
  • Hypertension treatment naïve patients, defined as those patients who have never been treated with antihypertensive medications or have been off any hypertensive treatment for a period of 12 weeks or longer.
  • Willing to refrain from using any antihypertensive treatments, other than the product, including herbal supplements, systemic use of , chronic use of NSAIDS, any antihypertensive agents, such as beta-blockers, diuretics, ACE inhibitors, CA channel blockers, Alpha blockers, Central Acting agents and vasodilators.
  • Ability to comprehend and comply with procedures
  • Agree to commit to participate in the current protocol
  • Provide written prior to any study procedure being performed (all subjects should be able to understand the informed consent form and any other documents that subjects are required to read)

Exclusion criteria

Exclusion Criteria:

  • Pregnant and/or lactating women
  • Patients on treatment for Benign Prostatic Hyperplasia (BPH)
  • history of cardiovascular disease (i. e. PCI, CABG MI (if event occurred 12 months), atrial fibrillation, frequent PAC, cardiac rhythm disorder, syncope, valve repair/replacement, heart transplantation, PTA, peripheral bypass surgery, endarterectomy, unstable angina, , stroke and NYHF category II, II and IV heart failure.
  • Patients with renal failure, significant kidney or renal disease defined as having creatinine level of mg/dL
  • Presence of any condition (medical, psychological, social, or geographical), actual or anticipated, that the Investigator feels would restrict or limit the patient's successful participation for the duration of the study
  • History of migraines and/or anxiety, where patient is unable to refrain from the use of beta blockers
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation.
  • The participant has been previously randomized in this study
  • Subjects with clinical diagnosis of Type I Diabetes
  • Subjects with arm circumference of 42 cm
  • Any condition that would prevent the subject from participating in the trial in the opinion of the evaluation physician
  • The participant has received an product within 30 days prior to randomization
  • Prior use of any product containing B244 or Nitrosomonas eutropha
  • Unable to lie flat or sit for 15 minutes
  • Concurrent participation in other trials
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
132 participants (actual)

Study arms

  • Active comparator
    B244 4 pumps applied to the face

    4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.

    Biological: B244

  • Active comparator
    B 244 8 Pumps applied to face and torso

    8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.

    Biological: B244

  • Sham comparator
    Vehicle 4 pumps applied to the face

    4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.

    Biological: Vehicle

  • Sham comparator
    Vehicle 8 pumps applied to face and torso

    8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.

    Biological: Vehicle

Interventions

  • BiologicalB244

    odorless suspension

  • BiologicalVehicle

    odorless suspension

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0

    Safety and tolerability endpoints will consist of all treatment related adverse events reporting during the study duration.

    Time frame: Baseline-6 weeks

  2. Difference in Mean in Clinic Systolic BP Between the Active and Vehicle Groups

    Clinical systolic blood pressure (BP) readings were obtained at every visit using a calibrated electronic sphygmomanometer. Three measurements were taken at each visit. The average of the second and third readings was documented. Data was analyzed using mixed-effects model repeated measures (MMRM). Difference was calculated as the change from Baseline to Day 28.

    Time frame: Baseline-Week 4

Secondary outcomes

  1. Difference in Mean in Clinic Diastolic BP Between the Active and Vehicle Group

    Clinical diastolic blood pressure (BP) readings were obtained at every visit using a calibrated electronic sphygmomanometer. Three measurements were taken at each visit. The average of the second and third readings was documented. Data was analyzed using mixed-effects model repeated measures (MMRM). Difference was calculated as the change from Baseline to Day 28.

    Time frame: Baseline-Week 4

  2. Difference in Mean Ambulatory Systolic and Diastolic Daytime Blood Pressure

    An ambulatory blood pressure measurement (ABPM) device was placed on a subject's arm during the clinic visit to record 24-hour blood pressure and heart rate measurements.

    Time frame: Baseline-Week 4

Other outcomes

  1. Difference in Inflammatory Biomarkers Between Active and Vehicle Groups

    To evaluate if B244 administration on the skin twice daily will affect the levels of immune biomarkers.

    Time frame: Baseline-Week 4

  2. Microbial Content

    Evaluate if B244 administration on skin twice daily will affect the microbial content on collected skin swab samples.

    Time frame: Baseline, Day 28, Day 42

  3. Microbial Composition

    Evaluate if B244 administration on skin twice daily will affect the microbial composition on collected skin samples.

    Time frame: Baseline, Day 28, Day 42

07

Results

Posted Aug 15, 2022

Participant flow

Participant flow — Overall Study
MilestoneB244 4 Pumps Applied to the FaceB 244 8 Pumps Applied to Face and TorsoVehicle 4 Pumps Applied to the FaceVehicle 8 Pumps Applied to Face and Torso
Started33333333
Completed29303128
Not completed4325
Withdrew: Lost to follow-up1123
Withdrew: Withdrawal by subject1101
Withdrew: Unplanned travel, family emergency, sponsor request, work schedule2101

Outcome measures

PrimaryNumber of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0

Safety and tolerability endpoints will consist of all treatment related adverse events reporting during the study duration.

Time frame:
Baseline-6 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
ParticipantsB244 4 Pumps Applied to the FaceB 244 8 Pumps Applied to Face and TorsoPooled Vehicle 4 or 8 Pumps Applied to the Face (and Torso for 8 Pumps)
At Least 1 Treatment Related TEAE114
At Least 1 Treatment Related Serious TEAE000
PrimaryDifference in Mean in Clinic Systolic BP Between the Active and Vehicle Groups

Clinical systolic blood pressure (BP) readings were obtained at every visit using a calibrated electronic sphygmomanometer. Three measurements were taken at each visit. The average of the second and third readings was documented. Data was analyzed using mixed-effects model repeated measures (MMRM). Difference was calculated as the change from Baseline to Day 28.

Time frame:
Baseline-Week 4
Reported as:
Least squares mean · mmHg
Difference in Mean in Clinic Systolic BP Between the Active and Vehicle Groups
mmHgB244 4 Pumps Applied to the FaceB 244 8 Pumps Applied to Face and TorsoPooled Vehicle 4 or 8 Pumps Applied to the Face (and Torso for 8 Pumps)
Difference in Mean in Clinic Systolic BP Between the Active and Vehicle Groups-2.61 ± 1.828-0.66 ± 1.834-2.93 ± 1.296
SecondaryDifference in Mean in Clinic Diastolic BP Between the Active and Vehicle Group

Clinical diastolic blood pressure (BP) readings were obtained at every visit using a calibrated electronic sphygmomanometer. Three measurements were taken at each visit. The average of the second and third readings was documented. Data was analyzed using mixed-effects model repeated measures (MMRM). Difference was calculated as the change from Baseline to Day 28.

Time frame:
Baseline-Week 4
Reported as:
Least squares mean · mmHg
Difference in Mean in Clinic Diastolic BP Between the Active and Vehicle Group
mmHgB244 4 Pumps Applied to the FaceB 244 8 Pumps Applied to Face and TorsoPooled Vehicle 4 or 8 Pumps Applied to the Face (and Torso for 8 Pumps)
Difference in Mean in Clinic Diastolic BP Between the Active and Vehicle Group-1.65 ± 1.377-2.25 ± 1.358-1.31 ± 0.975
SecondaryDifference in Mean Ambulatory Systolic and Diastolic Daytime Blood Pressure

An ambulatory blood pressure measurement (ABPM) device was placed on a subject's arm during the clinic visit to record 24-hour blood pressure and heart rate measurements.

Time frame:
Baseline-Week 4
Reported as:
Mean · mmHg
Difference in Mean Ambulatory Systolic and Diastolic Daytime Blood Pressure
mmHgB244 4 Pumps Applied to the FaceB 244 8 Pumps Applied to Face and TorsoPooled Vehicle 4 or 8 Pumps Applied to the Face (and Torso for 8 Pumps)
Systolic Blood Pressure-3.06 ± 9.388-0.21 ± 12.250-0.53 ± 7.619
Diastolic Blood Pressure-2.17 ± 5.327-0.82 ± 7.325-0.98 ± 5.911
Other pre-specifiedDifference in Inflammatory Biomarkers Between Active and Vehicle Groups

To evaluate if B244 administration on the skin twice daily will affect the levels of immune biomarkers.

Time frame:
Baseline-Week 4
Reported as:
Mean · units on a scale
Difference in Inflammatory Biomarkers Between Active and Vehicle Groups
units on a scaleB244 4 Pumps Applied to the FaceB 244 8 Pumps Applied to Face and TorsoPooled Vehicle 4 or 8 Pumps Applied to the Face (and Torso for 8 Pumps)
Difference in Inflammatory Biomarkers Between Active and Vehicle GroupsNA ± NANA ± NANA ± NA
Other pre-specifiedMicrobial Content

Evaluate if B244 administration on skin twice daily will affect the microbial content on collected skin swab samples.

Time frame:
Baseline, Day 28, Day 42

No measurements were reported for this outcome.

Other pre-specifiedMicrobial Composition

Evaluate if B244 administration on skin twice daily will affect the microbial composition on collected skin samples.

Time frame:
Baseline, Day 28, Day 42

No measurements were reported for this outcome.

Adverse events

Collected over Baseline-Week 6. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
B244 4 Pumps Applied to the Face0/33 (0%)0/33 (0%)4/33 (12.1%)
B 244 8 Pumps Applied to Face and Torso0/33 (0%)1/33 (3%)6/33 (18.2%)
Pooled Vehicle 4 or 8 Pumps Applied to the Face (and Torso for 8 Pumps)0/66 (0%)0/66 (0%)11/66 (16.7%)
Most frequent serious events
Most frequent serious events
EventB244 4 Pumps Applied to the FaceB 244 8 Pumps Applied to Face and TorsoPooled Vehicle 4 or 8 Pumps Applied to the Face (and Torso for 8 Pumps)
Exacerbation of depressionPsychiatric disorders0/331/330/66
Most frequent other events
Showing 10 of 20
Most frequent other events
EventB244 4 Pumps Applied to the FaceB 244 8 Pumps Applied to Face and TorsoPooled Vehicle 4 or 8 Pumps Applied to the Face (and Torso for 8 Pumps)
HeadacheNervous system disorders1/330/333/66
DizzinessNervous system disorders1/330/332/66
SciaticaNervous system disorders0/331/331/66
Glycosylated haemoglobin increasedInvestigations1/330/331/66
Weight increasedInvestigations1/330/332/66
Dry skinSkin and subcutaneous tissue disorders0/331/331/66
PruritusSkin and subcutaneous tissue disorders1/330/330/66
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/331/330/66
ArrhythmiaCardiac disorders0/331/330/66
PyrexiaGeneral disorders0/331/330/66

Baseline characteristics

Intent to Treat Population (ITT): All randomized subjects, analyzed according to treatment assigned.

Age, Customized
Age, Customized(Participants)B244 4 Pumps Applied to the FaceB 244 8 Pumps Applied to Face and TorsoVehicle 4 Pumps Applied to the FaceVehicle 8 Pumps Applied to Face and TorsoTotal
<60 years25232527100
≥60 years8108632
Sex: Female, Male
Sex: Female, Male(Participants)B244 4 Pumps Applied to the FaceB 244 8 Pumps Applied to Face and TorsoVehicle 4 Pumps Applied to the FaceVehicle 8 Pumps Applied to Face and TorsoTotal
Female1517131762
Male1816201670
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)B244 4 Pumps Applied to the FaceB 244 8 Pumps Applied to Face and TorsoVehicle 4 Pumps Applied to the FaceVehicle 8 Pumps Applied to Face and TorsoTotal
Hispanic or Latino96111238
Not Hispanic or Latino2427222194
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)B244 4 Pumps Applied to the FaceB 244 8 Pumps Applied to Face and TorsoVehicle 4 Pumps Applied to the FaceVehicle 8 Pumps Applied to Face and TorsoTotal
American Indian or Alaska Native11002
Asian00112
Native Hawaiian or Other Pacific Islander00000
Black or African American8136936
White2319262290
More than one race00000
Unknown or Not Reported10012
Weight
Weight(kg)B244 4 Pumps Applied to the FaceB 244 8 Pumps Applied to Face and TorsoVehicle 4 Pumps Applied to the FaceVehicle 8 Pumps Applied to Face and TorsoTotal
Mean89.32 ± 21.08489.04 ± 21.65486.56 ± 12.25188.59 ± 18.87188.38 ± 18.654
BMI
BMI(kg/m^2)B244 4 Pumps Applied to the FaceB 244 8 Pumps Applied to Face and TorsoVehicle 4 Pumps Applied to the FaceVehicle 8 Pumps Applied to Face and TorsoTotal
Mean30.139 ± 6.243830.427 ± 5.904729.306 ± 4.370730.304 ± 6.388630.044 ± 5.7332
BMI Category
BMI Category(Participants)B244 4 Pumps Applied to the FaceB 244 8 Pumps Applied to Face and TorsoVehicle 4 Pumps Applied to the FaceVehicle 8 Pumps Applied to Face and TorsoTotal
<30 kg/m^21916202277
≥30 kg/m^21417131155
Smoking History
Smoking History(Participants)B244 4 Pumps Applied to the FaceB 244 8 Pumps Applied to Face and TorsoVehicle 4 Pumps Applied to the FaceVehicle 8 Pumps Applied to Face and TorsoTotal
Never1922221982
Former676322
Current8451128
08

Study locations

10 sites
  • Central Research Associates
    Birmingham, Alabama 35205, United States
  • Elite Clinical Studies
    Phoenix, Arizona 85018, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Clinical Research Consulting
    Milford, Connecticut 06460, United States
  • AGA Clinical Trials
    Hialeah, Florida 33012, United States
  • ICCT Research International
    Chicago, Illinois 60611, United States
  • MedPharmics
    Metairie, Louisiana 70006, United States
  • Alternative Primary Care (Einstein Clinical Research)
    Silver Spring, Maryland 20190, United States
  • CHEAR Center
    Bronx, New York 10459, United States
  • Research Trials WorldWide
    Humble, Texas 77338, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2016 to primary completion in Apr 2017, 5 months.

Results were first posted in Aug 2022, 5 years 3 months after primary completion. A results delay was requested in Jul 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2016
First posted
Dec 21, 2016
StartActual
Nov 2016
Primary completionActual
Apr 25, 2017
CompletionActual
Jun 26, 2017
Results delay requested
Jul 28, 2020
Results first posted
Aug 15, 2022
Last update
Sep 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02998840
Lead sponsor
AOBiome LLC
Collaborators
Veristat, Inc.
Responsible party
Sponsor
First posted
Dec 21, 2016
Start date
Nov 2016
Primary completion
Apr 25, 2017
Completion
Jun 26, 2017
Results posted
Aug 15, 2022
Last update
Sep 15, 2022

Study contacts

Larry Weiss, MD
study director · Chief Medical Officer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitrosomonas eutropha D23

Start the discussion